Steven Bair, MD

Assistant Professor, Medicine-Hematology


FacultyPhoto
Medical School
  • MD, Case Western Reserve University School of Medicine (2014)
Undergraduate School
  • BA/BS, Seattle Pacific University (WA) (2007)
Internship
  • Hospital of the University of Pennsylvania (2015)
Residency
  • Hospital of the University of Pennsylvania, Internal Medicine (2017)
Fellowships
  • University of Pennsylvania Program, Hematology and Oncology (2020)
Languages
English
Department
Medicine-Hematology

Professional Titles

  • Assistant Professor

Recognitions

  • Jane Alavi Award for Excellence, Abramson Cancer Center (2018)
  • Award in Cardiology, Myron F. Kanye & Lawrence J. Lantern (2014)

Research Interests

My research interests revolve around the use of “big data” (i.e., EMR-based phenotyping as well as molecular characterization of disease) to improve outcomes in patients with lymphoma and, more generally, to spur advances in precision medicine.

Publications

  • Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 Oct;191(1):44-51. PubMed PMID: 32430944
  • Svoboda J, Bair SM, Landsburg DJ, Nasta SD, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2020 May 15. [Epub ahead of print] PubMed PMID: 32414850
  • Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 Jun;25(6):e993-e997. PubMed PMID: 32275786
  • Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020 Jan 1;126(9):1837-1855. PubMed PMID: 32073653
  • Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 Oct;25(10):878-885. PubMed PMID: 32720734
  • Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021 Jun 1;106(6):1705-1713. PubMed PMID: 32414850
  • Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski SM, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma. Blood Adv. 2023 Feb 3. [Epub ahead of print] PubMed PMID: 36735393
  • Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023 Dec 26;7(24):7485-7493. PubMed PMID: 37603594
  • Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023 Nov 14;7(21):6630-6638. PubMed PMID: 37595053
  • Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Jul 25;7(14):3516-3529. PubMed PMID: 36735393

Professional Memberships

  • American Society of Hematology, Member
  • American Society of Clinical Oncology, Member
  • American Medical Association, Member
  • American Medical Informatics Association, Member

Practice Locations

UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital

Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2017, 2017)
  • Hematology, Board Certification (2020, 2020)
Conditions & Treatments
  • Cancers - Lymphoma
  • Cancers
  • Cancers - Leukemia (Adult Chronic)
Clinical Interests
My clinical interests revolve around the care of patients with all types of lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL), indolent B-cell lymphoma, aggressive B-cell lymphoma, as well as other types of lymphoma.

Care Philosophy
I am keen to provide the best clinical care possible for patients with all of types of lymphoma. I believe that it is imperative to understand each patient and their disease to the greatest extent possible in order to provide the right treatment for the right person at the right time.